Tags

Type your tag names separated by a space and hit enter

Lanadelumab to treat hereditary angioedema.
Drugs Today (Barc) 2019; 55(7):439-448DT

Abstract

Lanadelumab is a human monoclonal antibody against plasma kallikrein indicated for prevention of attacks of hereditary angioedema (HAE). HAE is caused by SERPING1 gene mutations resulting in decreased or dysfunctional plasma protease C1 inhibitor (C1-INH) leading to a loss of inhibition of plasma kallikrein activity with subsequent cleavage of high-molecular weight kininogen and release of bradykinin. There is a clear need for a non-plasma-derived, safe, effective and convenient prophylaxis of HAE attacks to reduce patients' daily burden of disease and disability. The percentage of patients who were attack-free for the last 16 weeks of a controlled study was 77% in the group receiving 300 mg lanadelumab every 2 weeks, compared with 3% with placebo. The most common side effects were mild injection-site reactions. Lanadelumab has the potential to change the approach from on-demand treatment to prophylaxis in HAE. Future studies will have to confirm long-term safety and efficacy of prophylactic long-term inhibition of plasma kallikrein.

Authors+Show Affiliations

Department of Dermatology and Allergy, Comprehensive Allergy Center, Hannover Medical School, Hannover, Germany. wedi.bettina@mh-hannover.de.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31347612

Citation

Wedi, B. "Lanadelumab to Treat Hereditary Angioedema." Drugs of Today (Barcelona, Spain : 1998), vol. 55, no. 7, 2019, pp. 439-448.
Wedi B. Lanadelumab to treat hereditary angioedema. Drugs Today. 2019;55(7):439-448.
Wedi, B. (2019). Lanadelumab to treat hereditary angioedema. Drugs of Today (Barcelona, Spain : 1998), 55(7), pp. 439-448. doi:10.1358/dot.2019.55.7.2985293.
Wedi B. Lanadelumab to Treat Hereditary Angioedema. Drugs Today. 2019;55(7):439-448. PubMed PMID: 31347612.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lanadelumab to treat hereditary angioedema. A1 - Wedi,B, PY - 2019/7/27/entrez PY - 2019/7/28/pubmed PY - 2019/8/1/medline KW - Hereditary angioedema KW - Lanadelumab KW - Monoclonal antibodies KW - Plasma kallikrein inhibitors SP - 439 EP - 448 JF - Drugs of today (Barcelona, Spain : 1998) JO - Drugs Today VL - 55 IS - 7 N2 - Lanadelumab is a human monoclonal antibody against plasma kallikrein indicated for prevention of attacks of hereditary angioedema (HAE). HAE is caused by SERPING1 gene mutations resulting in decreased or dysfunctional plasma protease C1 inhibitor (C1-INH) leading to a loss of inhibition of plasma kallikrein activity with subsequent cleavage of high-molecular weight kininogen and release of bradykinin. There is a clear need for a non-plasma-derived, safe, effective and convenient prophylaxis of HAE attacks to reduce patients' daily burden of disease and disability. The percentage of patients who were attack-free for the last 16 weeks of a controlled study was 77% in the group receiving 300 mg lanadelumab every 2 weeks, compared with 3% with placebo. The most common side effects were mild injection-site reactions. Lanadelumab has the potential to change the approach from on-demand treatment to prophylaxis in HAE. Future studies will have to confirm long-term safety and efficacy of prophylactic long-term inhibition of plasma kallikrein. SN - 1699-3993 UR - https://www.unboundmedicine.com/medline/citation/31347612/Lanadelumab_to_treat_hereditary_angioedema_ L2 - http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summaryn_pr?p_JournalId=4&p_RefId=2985293 DB - PRIME DP - Unbound Medicine ER -